PET/CT中基于多价成纤维细胞活化蛋白抑制剂的放射性药物：从癌症诊断到诊疗一体化。
Multivalent FAPI-based radiopharmaceuticals in PET/CT: from cancer diagnostics to theranostics.
作者信息
Zhao Taoqian, Liang Steven H
机构信息
Department of Radiology and Imaging Sciences, Emory University Atlanta, Georgia 30322, United States.
出版信息
Am J Nucl Med Mol Imaging. 2025 Apr 15;15(2):82-86. doi: 10.62347/TUZI7617. eCollection 2025.
Abstract
Radiopharmaceuticals targeting fibroblast activation protein (FAP) have rapidly emerged as innovative agents for cancer imaging and therapy. By selectively binding to cancer-associated fibroblasts (CAFs), radiolabeled FAP inhibitors (FAPIs) enable high-contrast PET/CT imaging across diverse tumor types. This article highlights recent advances in FAPI PET/CT imaging, with particular focus on the influence of multivalency effect in radiotracer development.
摘要
靶向成纤维细胞活化蛋白（FAP）的放射性药物已迅速成为癌症成像和治疗的创新药物。通过选择性地与癌症相关成纤维细胞（CAF）结合，放射性标记的FAP抑制剂（FAPI）能够对多种肿瘤类型进行高对比度PET/CT成像。本文重点介绍了FAPI PET/CT成像的最新进展，特别关注多价效应在放射性示踪剂开发中的影响。
相似文献
1
Multivalent FAPI-based radiopharmaceuticals in PET/CT: from cancer diagnostics to theranostics.PET/CT中基于多价成纤维细胞活化蛋白抑制剂的放射性药物：从癌症诊断到诊疗一体化。
Am J Nucl Med Mol Imaging. 2025 Apr 15;15(2):82-86. doi: 10.62347/TUZI7617. eCollection 2025.
2
Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.成纤维细胞激活蛋白靶向放射性示踪剂的研发，以提高肿瘤滞留性。
J Nucl Med. 2019 Oct;60(10):1421-1429. doi: 10.2967/jnumed.118.224469. Epub 2019 Mar 8.
3
Clinical Evaluation of Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin αβ in Various Cancer Types.Ga-FAPI-RGD 用于各种癌症类型中成纤维细胞激活蛋白和整合素 αβ 的成像的临床评估。
J Nucl Med. 2023 Aug;64(8):1210-1217. doi: 10.2967/jnumed.122.265383. Epub 2023 May 4.
4
Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: Cu- and Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models.肿瘤基质中成纤维细胞激活蛋白的治疗策略：胰腺癌细胞异种移植鼠模型中的 Cu-和 Ac 标记的 FAPI-04。
J Nucl Med. 2020 Apr;61(4):563-569. doi: 10.2967/jnumed.119.233122. Epub 2019 Oct 4.
5
Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers.镓-FAPI PET/CT：不同癌症患者中两种含 DOTA 的 FAP 靶向剂的生物分布和初步剂量估算。
J Nucl Med. 2019 Mar;60(3):386-392. doi: 10.2967/jnumed.118.215913. Epub 2018 Aug 2.
6
Head-to-Head Comparison of [ Ga]Ga-FAPI-46-PET/CT and [F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer.头对头比较[Ga]Ga-FAPI-46-PET/CT 和 [F]F-FDG-PET/CT 对头颈部癌症放疗计划的作用。
Mol Imaging Biol. 2022 Dec;24(6):986-994. doi: 10.1007/s11307-022-01749-7. Epub 2022 Jun 30.
7
Design and Development of Tc-Labeled FAPI Tracers for SPECT Imaging and Re Therapy.Tc 标记 FAPI 示踪剂的设计与开发用于 SPECT 成像和再治疗。
J Nucl Med. 2020 Oct;61(10):1507-1513. doi: 10.2967/jnumed.119.239731. Epub 2020 Mar 13.
8
A rationally designed nuclei-targeting FAPI 04-based molecular probe with enhanced tumor uptake for PET/CT and fluorescence imaging.一种基于合理设计的靶向细胞核的 FAPI 04 分子探针，具有增强的肿瘤摄取能力，可用于 PET/CT 和荧光成像。
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1593-1604. doi: 10.1007/s00259-024-06691-0. Epub 2024 Mar 21.
9
Heterogeneity of fibroblast activation protein expression in the microenvironment of an intracranial tumor cohort: head-to-head comparison of gallium-68 FAP inhibitor-04 (Ga-FAPi-04) and fluoride-18 fluoroethyl-L-tyrosine (F-FET) in positron emission tomography-computed tomography imaging.颅内肿瘤队列微环境中成纤维细胞活化蛋白表达的异质性：正电子发射断层扫描-计算机断层扫描成像中镓-68 FAP抑制剂-04（Ga-FAPi-04）与氟-18氟乙基-L-酪氨酸（F-FET）的直接比较
Quant Imaging Med Surg. 2024 Jul 1;14(7):4450-4463. doi: 10.21037/qims-24-82. Epub 2024 Jun 27.
10
Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers.成纤维细胞激活蛋白抑制剂（FAPI）PET 用于头颈部癌症的诊断和先进的靶向放射治疗。
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2836-2845. doi: 10.1007/s00259-020-04859-y. Epub 2020 May 23.
本文引用的文献
1
Development of [Ga]Ga/[Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention.含硝基咪唑部分的[镓]镓/[镥]镥-DOTA-NI-FAPI-04作为具有改善肿瘤摄取和滞留的新型FAPI放射性示踪剂的开发。
J Med Chem. 2025 Jan 9;68(1):348-360. doi: 10.1021/acs.jmedchem.4c02015. Epub 2024 Dec 22.
2
Preclinical Evaluation of Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors.Lu-OncoFAP-23 的临床前评估，一种用于实体瘤的多价 FAP 靶向放射性药物治疗剂。
J Nucl Med. 2024 Oct 1;65(10):1604-1610. doi: 10.2967/jnumed.124.268200.
3
Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with F-FDG.Ga-FAP-2286 PET 用于实体瘤：生物分布、剂量学和与 F-FDG 的比较。
J Nucl Med. 2024 Jun 3;65(6):938-943. doi: 10.2967/jnumed.123.267281.
4
Ga-FAPI PET/CT as an Alternative to F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma.镓-FAPI PET/CT 可作为侵袭性小叶乳腺癌成像的 F-FDG PET/CT 替代方法。
J Nucl Med. 2024 Apr 1;65(4):512-519. doi: 10.2967/jnumed.123.266798.
5
Design, Preclinical Evaluation, and Clinical Translation of Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.镓-FAPI-LM3 的设计、临床前评估和临床转化，一种用于鼻咽癌 PET 成像的双价分子。
J Nucl Med. 2024 Mar 1;65(3):394-401. doi: 10.2967/jnumed.123.266183.
6
FAPI PET/CT Imaging-An Updated Review.FAPI PET/CT成像——最新综述
Diagnostics (Basel). 2023 Jun 9;13(12):2018. doi: 10.3390/diagnostics13122018.
7
Radiochemistry for positron emission tomography.正电子发射断层成像中的放射性化学
Nat Commun. 2023 Jun 5;14(1):3257. doi: 10.1038/s41467-023-36377-4.
8
Fibroblast Activation Protein Inhibitor PET in Pancreatic Cancer.成纤维细胞激活蛋白抑制剂 PET 在胰腺癌中的应用。
PET Clin. 2023 Jul;18(3):295-308. doi: 10.1016/j.cpet.2023.02.001. Epub 2023 Apr 6.
9
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.成纤维细胞激活蛋白靶向放射性核素治疗：首次（临床前）研究的背景、机遇和挑战。
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):1906-1918. doi: 10.1007/s00259-023-06144-0. Epub 2023 Feb 23.
10
F- or Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention.F-或 Lu 标记的成纤维细胞激活蛋白双价配体，具有高肿瘤摄取和滞留。
Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2705-2715. doi: 10.1007/s00259-022-05757-1. Epub 2022 Mar 15.
Zotero 插件